AtaiBeckley Inc. (ATAI) · Sep 11, 2026 · Acquisition
Merger completed — $6.75 cash plus up to $2.50 in contingent CVR payments
Lilly’s acquisition is complete: shareholders receive $6.75 in cash, while up to $2.50 more depends on future drug milestones.
This is confirmation of a previously announced deal, not a fresh surprise. AtaiBeckley disclosed the Lilly merger on July 15, 2026, and the September 11 filing confirms that it closed on schedule. 〔0〕 Because the transaction terms were already public, the market had largely priced in this outcome; there is no clean beat-or-miss comparison.
Shareholders receive $6.75 per share immediately, with additional value dependent on development milestones. Each share converts into $6.75 in cash plus one CVR worth up to another $2.50 if specified VLS-01 and BPL-003 milestones are achieved. 〔1〕 The headline consideration is therefore $6.75 realized value, while the extra $2.50 is uncertain, non-transferable and not exchange-listed rather than cash delivered at closing.
The public-company investment case ends with the closing. AtaiBeckley became Lilly’s wholly owned subsidiary, its common stock trading was requested to be suspended, and Nasdaq delisting and termination of reporting obligations will follow.
Net read: in line and priced in. The filing delivers exactly the expected completion mechanics, with no new operating results, guidance change or deal-term improvement. The remaining investor-relevant catalyst is whether Lilly advances the programs far enough to trigger the CVR payments, beginning with potential Phase 3 initiation for VLS-01 by September 11, 2030.
VLS-01 Phase 3 initiation by September 11, 2030
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!